Free Annual ReportsBristol Myers Squibb Co $ 46.52
+1.12
Digital Company Profile
| Last Trade: | 46.52 |
| Trade Time: | Sep 18 06:40 PM Eastern Daylight Time |
| Change: | 1.12 (2.47 %) |
| Prev Close: | 45.40 |
| Open: | 45.48 |
| Bid: | 46.53 |
| Ask: | 46.54 |
Quotes displayed are delayed by 15 minutes. Market data is provided by Xignite
Get BMY Trend Analysis
-
it has outperformed the S&P 500 by 23%
ETF Alternatives
| Ticker | Name | Weight | % Change |
|---|---|---|---|
| IHE | iShares U.S. Pharmaceuticals ETF | 5.59% | +0.56% |
| PPH | Market Vectors Pharmaceutical ETF | 4.57% | +1.02% |
| PJP | PowerShares Dynamic Pharmaceuticals | 4.21% | +0.70% |
| XLV | Health Care Select Sector SPDR | 3.65% | +0.62% |
| IYH | iShares U.S. Healthcare ETF | 3.37% | +0.67% |
| GVT | Columbia Select Large Cap Value ETF | 3.33% | +0.00% |
| VHT | Vanguard Health Care ETF | 3.03% | +0.59% |
| DIV | Global X SuperDividend US ETF | 2.29% | +1.49% |
| USMV | iShares MSCI USA Minimum Volatility | 1.48% | +1.65% |
Competitors
| Ticker | Name | Volume | % Change |
|---|---|---|---|
| PFE | Pfizer Inc | 30.22M | +1.40% |
| MRK | Merck & Co Inc | 14.01M | +0.81% |
| JNJ | Johnson & Johnson | 10.09M | +0.95% |
| ELTP | Elite Pharmaceuticals Inc | 9.90M | +21.50% |
| DNDN | Dendreon Corp | 7.33M | +3.51% |
Insider Transactions
| Date | Name | Title | Volume | Trade Price | Holding Change |
|---|---|---|---|---|---|
| 7/29/2013 | CORNELIUS JAMES M | Director | -5,000 | $43.81 | -0.77% |
| 7/29/2013 | CORNELIUS JAMES M | Director | 2,500 | $24.96 | 0.39% |
| 7/29/2013 | CORNELIUS JAMES M | Director | 2,500 | $26.25 | 0.39% |
| 7/29/2013 | CORNELIUS JAMES M | Director | -100,000 | $43.92 | -15.57% |
| 6/30/2013 | CORNELIUS JAMES M | Director | 559 | $44.69 | 0.09% |
Data provided by Insiderslab.com.
To read detailed Insider Trading Research Report for (
BMY ), click here.
BMY Stock Analysis
-
AstraZeneca Goes Back To The M&A Well Yet Again
-
Better Margins Can't Hide Merck's Growth Challenges
-
Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
-
Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
-
Glaxo Seeks Tafinlar-Mekinist Approval - Analyst Blog
-
Positive Data on BMY/ Pfizer's Eliquis - Analyst Blog
-
Free Managed Futures Book
Get the four benefits of managed futures as outlined in this booklet. -
View the Portfolios of the Worlds Top Investors, FREE!
Learn from Warren Buffett, George Soros and More! -
7 Proven Strategies for Market-Stomping Stocks
Discover Investing Strategies that will Benefit Every Investor Today!
Free Annual Reports